Epsilon M&A Deal Report - Bioclinic (SELAS BIO-CLINIC)
Transaction Multiples for the Valuation of Private Companies
Private group led by Idia Capital Investissement, Amundi Private Equity Funds, Socadif and Andera Partners (ActoMezz) / Bioclinic (SELAS BIO-CLINIC)
No EMAT :
94685
Announced Date :
21/01/2019
Type :
SBO (Secondary Buy Out) ,Exit
Deal Value :
Yes
Acquirer :
Private group led by Idia Capital Investissement, Amundi Private Equity Funds, Socadif and Andera Partners (ActoMezz)
Target :
Bioclinic (SELAS BIO-CLINIC)
Country :
Hauts-De-Seine
Sector of activity :
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Medical Diagnostic Laboratory
Business Description :
Founded in 1995 by Dr Philippe DABI, Bioclinic operates medical analysis laboratories in the Ile-de-France region. > 80 biologist doctors and pharmacists, together with nearly 700 employees, work...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
||||||
| Current |
|
Rating :
*
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Medical Diagnostic Laboratory » = 51
| Date | Acquirer | Target | Country | Multiples | See details |
| 01/02/2018 | Private Group led by Axcel Management | Invima (Isadora) | Sweden | * | 94545 |
| 25/06/2018 | STADA Arzneimittel | Nizoral Shampoo Brand Rights in EMEA | * | 94522 |
Source: Epsilon Research / EMAT
